Mendelian randomization identifies OX40 as a potential mediator of the effects of cigarette smoking on palmoplantar pustulosis
- PMID: 40674711
- DOI: 10.1093/bjd/ljaf280
Mendelian randomization identifies OX40 as a potential mediator of the effects of cigarette smoking on palmoplantar pustulosis
Conflict of interest statement
Conflicts of interest: A.D.B. has received consultancy fees from Boehringer Ingelheim. R.B.W. has received grants and/or consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, Galderma, GSK, Janssen, LEO, Lilly, Meiji Pharma, Novartis, Pfizer, RAPT Pharmaceuticals, Sanofi, Sun Pharma, UCB & UNION. S.V. was an employee of Boehringer Ingelheim. F.C. has received grant funding and consultancy fees from Boehringer Ingelheim.
Grants and funding
LinkOut - more resources
Full Text Sources
